Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | YAP1 | P46937 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4444035 | 0.84 | SIGMAR1 (0.42) | GPR119HSD11B2ATMKMT2AMAPK1 | |
| SCHEMBL3614064 | 0.83 | KEAP1 (0.41) | GPR119HSD11B2ATMKMT2AKDM4E | |
| SCHEMBL13110173 | 0.83 | KEAP1 (0.41) | GPR119HSD11B2ATMKMT2AKDM4E | |
| SCHEMBL3614066 | 0.83 | KEAP1 (0.41) | GPR119HSD11B2ATMKMT2AKDM4E | |
| SCHEMBL7504057 | 0.83 | MEN1 (0.44) | HSD11B2KMT2AMEN1 | |
| SCHEMBL6719414 | 0.83 | MEN1 (0.39) | HSD11B2KMT2AMEN1KDM4ESPHK1 | |
| SCHEMBL6821991 | 0.81 | GPR119 (0.36) | GPR119ATMKMT2AMAPK1MEN1 | |
| SCHEMBL7494707 | 0.80 | SPHK1 (0.43) | HSD11B2KDM4EPKMSPHK1BRD4 | |
| SCHEMBL6719409 | 0.78 | ELANE (0.41) | GPR119ATMKMT2AMAPK1 | |
| SCHEMBL7499182 | 0.78 | ELANE (0.41) | GPR119ATMKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | GPR119 201/4885HSD11B2 702/4885ATM 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.